Medite Cancer Diagnostics Inc
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controll… Read more
Medite Cancer Diagnostics Inc (MDIT) - Total Liabilities
Latest total liabilities as of September 2018: $11.21 Million USD
Based on the latest financial reports, Medite Cancer Diagnostics Inc (MDIT) has total liabilities worth $11.21 Million USD as of September 2018.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medite Cancer Diagnostics Inc - Total Liabilities Trend (2013–2017)
This chart illustrates how Medite Cancer Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medite Cancer Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Medite Cancer Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SPANISH MTN GLD
MU:S3Y
|
Germany | €1.15 Million |
|
QUESTERRE ENERGY-A
MU:QE1
|
Germany | €33.31 Million |
|
PT Timah Tbk
MU:TIH1
|
Germany | €5.03 Trillion |
|
ZHUGUANG HOLDINGS
BE:NA7
|
Germany | €29.57 Billion |
|
Alchemy Investments Acquisition Corp 1 Warrants
NASDAQ:ALCYW
|
USA | $6.52 Million |
|
SPC Power Corp
PSE:SPC
|
Philippines | ₱1.55 Billion |
Liability Composition Analysis (2013–2017)
This chart breaks down Medite Cancer Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medite Cancer Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medite Cancer Diagnostics Inc (2013–2017)
The table below shows the annual total liabilities of Medite Cancer Diagnostics Inc from 2013 to 2017.
| Year | Total Liabilities | Change |
|---|---|---|
| 2017-12-31 | $10.18 Million | +6.64% |
| 2016-12-31 | $9.55 Million | +3.64% |
| 2015-12-31 | $9.21 Million | -9.80% |
| 2014-12-31 | $10.21 Million | +137.90% |
| 2013-12-31 | $4.29 Million | -- |